Company news
Yulong Eco-materials Limited (OTC:YECO) news
Yulong Eco-materials Limited news releases on 6ix. Latest, Jan 15, 2025: EV Biologics Develops Breakthrough Exosome-Based Therapeutics for Clinical Trials
Press releases & updates
EV Biologics Develops Breakthrough Exosome-Based Therapeutics for Clinical Trials
January 14, 2025
EV Biologics Updates on Funding and Sales
October 1, 2023
EV Biologics Completes Production of Cutting-Edge MSC Exosome-Based Therapeutic
August 15, 2023
EV Biologics Appoints Senior Investment Banker as Corporate Finance Director
August 6, 2023
EV Biologics Hires Senior Chief Financial Officer
August 1, 2023
EV Biologics Signs Exclusive Distribution Agreement for South America
May 14, 2023
EV Biologics Generates Mesenchymal Stem Cell Lines
February 20, 2023
EV Biologics Updates on Excyte Subsidiary Funding
January 2, 2023
EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX
November 13, 2022
EV Biologics Launches Excyte with $100 million Valuation
August 14, 2022
EV Biologics Signs MSA with LONZA Cell & Gene Therapy
May 16, 2022
EV Biologics Isolates Primary Cells for Nanoparticle Production & Accelerated Cell Line Development
April 11, 2022
EV Biologics Updates on FINRA Filings
March 8, 2022
EV Biologics Updates on FINRA
January 17, 2022
EV Biologics Updates on NFT Dividend
November 11, 2021
EV Biologics Signs Listing Agreement With INX
November 10, 2021
EV Biologics Chief Medical Officer Publication on COVID-19 & Exosomes
October 27, 2021
EV Biologics Updates on NFT Minting
September 27, 2021
EV Biologics Updates on NFT Warrant Dividend Distribution
August 29, 2021
EV Biologics Briefs Shareholders on Market Cap Peer Comparison
August 11, 2021
EV Biologics NFT Dividend Information
August 8, 2021
EV Biologics NFT Dividend Warrant Date
July 29, 2021
EV Biologics Starts Custom Cell Isolation with Lonza Cell Bio Services
July 27, 2021
EV Biologics Unveils NFT Dividend Warrant
July 25, 2021
EV Biologics Signs LOI with Lonza Cell & Gene Therapy
July 21, 2021
EV Biologics NFT Dividend Update
July 18, 2021
EV Biologics Announces NFT Dividend
July 13, 2021
EV Biologics is now Pink Current
June 13, 2021
EV Biologics Updates Shareholders on Name and Symbol Change
May 18, 2021
EV Biologics Confirms Funding to Commence Cell Line Generation & Advance Exosome Research
April 7, 2021
EV Biologics Designs Process for Scalable Exosome Biopharmaceutical Manufacturing
February 21, 2021
EV Biologics Has Engaged Foley & Lardner LLP for Legal Counsel in Intellectual Property
January 25, 2021
EV Biologics Update for 2021
January 3, 2021
EV Biologics Signs Funding Agreement for Biotech Security Token Offering
December 1, 2020
EV Biologics is Targeting Pink Current
November 9, 2020
EV Biologics To Perform Specialized Analysis of EV Biopharmaceuticals at Vanderbilt University
September 28, 2020
Yulong to List its Securitized Token on CryptoSX
September 22, 2020
Yulong to Issue the Worlds’ First Biotech Securitized Token Offering
September 20, 2020
Yulong Intends to Develop a Cell Biologics Incubator Lab
September 8, 2020
Yulong Recruits Dr. Jason Sanders as CMO
August 30, 2020